<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130025</url>
  </required_header>
  <id_info>
    <org_study_id>IN 0901 INT</org_study_id>
    <secondary_id>2009-018141-20</secondary_id>
    <nct_id>NCT01130025</nct_id>
  </id_info>
  <brief_title>Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer</brief_title>
  <official_title>Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Innohep® in preventing the
      recurrence of VTE in patients with active cancer who have had an acute VTE episode.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite end-point represented by the time in days from randomisation to the first occurrence of VTE</measure>
    <time_frame>6 months</time_frame>
    <description>Symptomatic non-fatal DVTs.
Symptomatic non-fatal PEs.
Fatal PE.
Incidental proximal DVT (popliteal vein or higher).
Incidental proximal PE (segmental arteries or larger).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in days from randomisation to the first occurrence of VTE.</measure>
    <time_frame>6 months</time_frame>
    <description>The 5 individual components of the composite primary efficacy endpoint.
A composite endpoint of symptomatic DVT and/or PE, including fatal PE.
Safety endpoints will consist of bleeding and overall mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Innohep®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-term treatment with Innohep® only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Innohep®</intervention_name>
    <description>Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.</description>
    <arm_group_label>Innohep®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of active cancer.

          -  Symptomatic and objectively confirmed VTE.

          -  ≥ 18 years of age or above the legal age of consent as per country specific
             regulations.

          -  Patients with Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or
             2.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Life expectancy &lt; 6 months.

          -  Patients with basal cell carcinoma or non-melanoma skin cancer.

          -  Creatinine clearance ≤ 20 ml/min.

          -  Contra-indications to anticoagulation.

          -  Known hypersensitivity to the investigational product (Innohep®) or the reference
             product (warfarin).

          -  History of heparin-induced thrombocytopenia (HIT).

          -  Pre-randomisation therapeutic anticoagulant treatment for acute VTE administered for
             more than 72 hours prior to randomisation.

          -  Patients unlikely to comply with the protocol.

          -  Participation in another interventional study.

          -  Pregnant or breast-feeding women.

          -  Women of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnes Y. Y. Lee, MD, MSc, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Thrombosis, Division of Hematology, University of British Columbia, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diamond Health Care Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2010</study_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

